References
- Varnamkhasti BS, Jafari S, Taghavi F, Alaei L, Izadi Z, Lotfabadi A, Dehghanian M, Jaymand M, Derakhshankhah H, Saboury AA. Cell-penetrating peptides: as a promising theranostics strategy to circumvent the blood-brain barrier for CNS diseases. Curr Drug Deliv. 2020;17(5):35–63. doi:https://doi.org/10.2174/1567201817666200415111755.
- Yeste J, Illa X, Alvarez M, Villa R. Engineering and monitoring cellular barrier models. J Biol Eng. 2018;12(1):18. doi:https://doi.org/10.1186/s13036-018-0108-5.
- Khafagy ES, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev. 2012;64(6):531–539. doi:https://doi.org/10.1016/j.addr.2011.12.014.
- Zou LL, Ma JL, Wang T, Yang TB, Liu CB. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Curr Neuropharmacol. 2013;11(2):197–208. doi:https://doi.org/10.2174/1570159X11311020006.
- Bernardes N, Fialho AM. Perturbing the dynamics and organization of cell membrane components: a new paradigm for cancer-targeted therapies. Int J Mol Sci. 2018;19(12):3871. doi:https://doi.org/10.3390/ijms19123871.
- Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, Pavão MS, Tzanakakis GN, Karamanos NK. Glycosaminoglycans: key players in cancer cell biology and treatment. The FEBS J. 2012;279(7):1177–1197. doi:https://doi.org/10.1111/j.1742-4658.2012.08529.x.
- Jobin M-L, Alves ID. On the importance of electrostatic interactions between cell penetrating peptides and membranes: a pathway toward tumor cell selectivity? Biochimie. 2014;107:154–159. doi:https://doi.org/10.1016/j.biochi.2014.07.022.
- Nikitovic D, Berdiaki A, Spyridaki I, Krasanakis T, Tsatsakis A, Tzanakakis GN. Proteoglycans-Biomarkers and targets in cancer therapy. Front Endocrinol. 2018;9:69. https://doi.org/https://doi.org/10.3389/fendo.2018.00069.
- Shin MC, Zhang J, Min KA, Lee K, Byun Y, David AE, He H, Yang VC. Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J Biomed Mater Res A. 2014;102(2):575–587. doi:https://doi.org/10.1002/jbm.a.34859.
- Shin MC, Zhang J, Min KA, He H, David AE, Huang Y, Yang VC. PTD-modified ATTEMPTS for enhanced toxin-based cancer therapy: an in vivo proof-of-concept study. Pharm Res. 2015;32:2690–2703. doi:https://doi.org/10.1007/s11095-015-1653-y.
- Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C. 2019;98:1252–1276. doi:https://doi.org/10.1016/j.msec.2019.01.066.
- Duncan R. Polymer therapeutics: top 10 selling pharmaceuticals - what next? JCR. 2014;190:371–380. doi:https://doi.org/10.1016/j.jconrel.2014.05.001.
- Yin H, Liao L, Fang J. Enhanced Permeability and Retention (EPR) effect based tumor targeting: the concept, application and prospect. JSM Clin Oncol Res. 2014;2:1010. doi:https://doi.org/10.5497/wjp.v4.i2.168.
- Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev. 2009;61(13):1117–1120. doi:https://doi.org/10.1016/j.addr.2009.08.001.
- Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131–135. doi:https://doi.org/10.1016/j.addr.2010.03.011.
- Maeda H. Maeda Polymer therapeutics and the EPR effect. J Drug Target. 2017;25(9–10):781–785. doi:https://doi.org/10.1080/1061186X.2017.1365878.
- Fang B, Jiang L, Zhang M, Ren FZ. A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively. Biochimie. 2013;95(2):251–257. doi:https://doi.org/10.1016/j.biochi.2012.09.020.
- Rusiecka I, Ruczyński J, Alenowicz M, Rekowski P, Kocić, I. Transportan 10 improves the anticancer activity of cisplatin. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2016;389:485–497. doi:https://doi.org/10.1007/s00210-016-1219-5.
- Rusiecka I, Ruczyński J, Kozłowska A, Backtrog E, Mucha P, Kocić I, Rekowski P. TP10-Dopamine conjugate as a potential therapeutic agent in the treatment of parkinson’s disease. Bioconjug Chem. 2019;30(3):760–774. doi:https://doi.org/10.1021/acs.bioconjchem.8b00894.
- Ruczyński J, Rusiecka I, Turecka K, Kozłowska A, Alenowicz M, Gągało I, Kawiak A, Rekowski P, Waleron K, Kocić I. Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin. Sci Rep. 2019;9(1):3247. doi:https://doi.org/10.1038/s41598-019-40103-w.
- Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, et al. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol. 2008;378(3):565–580. doi:https://doi.org/10.1016/j.jmb.2008.02.066.
- Xie J, Gou Y, Zhao Q, Li S, Zhang W, Song J, Mou L, Li J, Wang K, Zhang B, et al. Antimicrobial activities and action mechanism studies of transportan 10 and its analogues against multidrug-resistant bacteria. J Peptide Sci. 2015;21(7):599–607. doi:https://doi.org/10.1002/psc.2781.
- Gomarasca M, Martins TFC, Greune L, Hardwidge PR, Schmidt MA, Rüter C. Bacterium-Derived cell-penetrating peptides deliver gentamicin to kill intracellular pathogens. Antimicrob Agents Chemother. 2017;61(4):e02545–e02616. doi:https://doi.org/10.1128/AAC.02545-16.
- Bárány-Wallje E, Andersson A, Gräslund A, Mäler L. NMR solution structure and position of transportation in neutral phospholipid bicelles. FEBS Lett. 2004;567(2–3):265–269. doi:https://doi.org/10.1016/j.febslet.2004.04.079.
- Eriksson OS, Geörg M, Sjölinder H, Sillard R, Lindberg S, Langel Ü, Jonsson AB. Identification of cell-penetrating peptides that are bactericidal to Neisseria meningitidis and prevent inflammatory responses upon infection. Antimicrob Agents Chemother. 2013;57(8):3704–3712. doi:https://doi.org/10.1128/AAC.00624-13.
- Xu J, Xu B, Shou D, Xia X, Hu Y. Preparation and evaluation of vancomycin-loaded n-trimethyl chitosan nanoparticles. Polymers. 2015;7(9):1850–1870. doi:https://doi.org/10.3390/polym7091488.
- Jafari S, Dizaj SM, Adibkia K. Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery. BioImpacts. 2015;5(2):103–111. doi:https://doi.org/10.15171/bi.2015.10.
- Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee RJ, Yang Z. Cell-Penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020;11:697. doi:https://doi.org/10.3389/fphar.2020.00697.
- Guidotti G, Brambilla L, Rossi D. Cell-Penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38(4):406–424. doi:https://doi.org/10.1016/j.tips.2017.01.003.
- Ruseska I, Zimmer A. Internalization mechanisms of cell-penetrating peptides. Beilstein J Nanotechnol. 2020;11:101–123. https://doi.org/https://doi.org/10.3762/bjnano.11.10.
- Ashrafuzzaman M. Nanoscale biophysics of the cell, first ed. ed. Springer; Heidelberg, Germany,2018
- Martín I, Teixidó M, Giralt E. Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E). Chembiochem: A European Journal of Chemical Biology. 2011;12(6):896–903. doi:https://doi.org/10.1002/cbic.201000679.
- Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 2009;69(2):537–546. doi:https://doi.org/10.1158/0008-5472.CAN-08-2932.
- Abuei H, Behbahani AB, Dehbidi GR, Pirouzfar M, Zare F, Farhadi A. Construction, expression, and purification of p28 as a cell-penetrating peptide with anticancer effects on Burkitt’s lymphoma cell line. SEMJ. 2019;20:e85190. doi:https://doi.org/10.5812/semj.85190.
- Yaghoubi A, Khazaei M, Avan A, Hasanian SM, Cho WC, Soleimanpour S. p28 bacterial peptide, as an anticancer agent. Front Oncol. 2020;10:1303. https://doi.org/https://doi.org/10.3389/fonc.2020.01303.
- Delaroche D, Cantrelle FX, Subra F, Van Heijenoort C, Guittet E, Jiao CY, Blanchoin L, Chassaing G, Lavielle S, Auclair C, et al. Cell-penetrating peptides with intracellular actin-remodeling activity in malignant fibroblasts. J Biol Chem. 2010;5(10):7712–7721. doi:https://doi.org/10.1074/jbc.M109.045872.
- Franz J, Lelle M, Peneva K, Bonn M, Weidner T. SAP(E) - A cell-penetrating polyproline helix at lipid interfaces. Biochim Biophys Acta. 2016;1858(9):2028–2034. doi:https://doi.org/10.1016/j.bbamem.2016.05.021.
- Martín I, Teixidó M, Giralt E. Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E). Chembiochem. 2011;12(6):896–903. doi:https://doi.org/10.1002/cbic.201000679.
- Tripathi PP, Arami H, Banga I, Gupta J, Gandhi S. Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy. Oncotarget. 2018;9(98):37252–37267. doi:https://doi.org/10.18632/oncotarget.26442.
- Madani F, Lindberg S, Langel Ü, Futaki S, Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011;2011:414729. https://doi.org/https://doi.org/10.1155/2011/414729.
- Lindgren M, Hällbrink M, Prochiantz A, Langel Ü. Cell-penetrating peptides. TIPS. 2000;21:99–103. doi:https://doi.org/10.1016/S0165-6147(00)01447-4.
- Ramsey JD, Flynn NH. Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther. 2015;154:78–86. https://doi.org/https://doi.org/10.1016/j.pharmthera.2015.07.003.
- Mishra A, Gordon V, Yang L, Coridan R, Wong G. HIV TAT forms pores in membranes by inducing saddle-splay curvature: potential role of bidentate hydrogen bonding. Angew Chem Int Ed Engl. 2008;47(16):2986–2989. doi:https://doi.org/10.1002/anie.200704444.
- Mishra A, Lai GH, Schmidt NW, Sun VZ, Rodriguez AR, Tong R, Tang L, Cheng J, Deming TJ, Kamei DT, et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci USA. 2011;108(41):16883–16888. doi:https://doi.org/10.1073/pnas.1108795108.
- Ciobanasu C, Siebrasse JP, Kubitscheck U. Cell-penetrating HIV1 TAT peptides can generate pores in model membranes. Biophys J. 2010;99(1):153–162. doi:https://doi.org/10.1016/j.bpj.2010.03.065.
- Berlose JP, Convert O, Derossi D, Brunissen A, Chassaing G. Conformational and associative behaviours of the third helix of antennapedia homeodomain in membrane-mimetic environments. Eur J Biochem. 1996;242(2):372–386. doi:https://doi.org/10.1111/j.1432-1033.1996.0372r.x.
- Kawamoto S, Takasu M, Miyakawa T, Morikawa R, Oda T, Futaki S, Nagao H. Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: importance of attractive force between cell-penetrating peptides and lipid head group. J Chem Phys. 2011;134(9):095103. doi:https://doi.org/10.1063/1.3555531.
- Islam MZ, Sharmin S, Levadnyy V, Alam Shibly SU, Yamazaki M. Effects of mechanical properties of lipid bilayers on the entry of cell-penetrating peptides into single vesicles. Langmuir. 2017;33(9):2433–2443. doi:https://doi.org/10.1021/acs.langmuir.6b03111.
- Islam MZ, Sharmin S, Moniruzzaman M, Yamazaki M. Elementary processes for the entry of cell-penetrating peptides into lipid bilayer vesicles and bacterial cells. Appl Microbiol Biotechnol. 2018;102(9):3879–3892. doi:https://doi.org/10.1007/s00253-018-8889-5.
- Sharmin S, Islam MZ, Karal MA, Shibly SUA, Dohra H, Yamazaki M. Effects of lipid composition on the entry of cell-penetrating peptide oligoarginine into single vesicles . Biochem. 2016;55(30):4154–4165. doi:https://doi.org/10.1021/acs.biochem.6b00189.
- Hasan M, Moghal MMR, Saha SK, Yamazaki M. The role of membrane tension in the action of antimicrobial peptides and cell-penetrating peptides in biomembranes. Biophys Rev. 2019;11(3):431–448. doi:https://doi.org/10.1007/s12551-019-00542-1.
- Choi YS, David AE. Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol. 2014;15(3):192–199. doi:https://doi.org/10.2174/1389201015666140617093331.
- Lindgren M, Langel Ü. Classes and prediction of cell-penetrating peptides. Methods Mol Biol. 2011;683:3–19. https://doi.org/https://doi.org/10.1007/978-1-60761-919-2_1.
- Magzoub M, Kilk K, Eriksson LE, Langel Ü, Gräslund A. Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochim Biophys Acta. 2001;1512(1):77–89. doi:https://doi.org/10.1016/s0005-2736(01)00304-2.
- Allolio C, Magarkar A, Jurkiewicz P, Baxová K, Javanainen M, Mason PE, Šachl R, Cebecauer M, Hof M, Horinek D, et al. Arginine-rich cell-penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore. Proc Natl Acad Sci USA. 2018;115(47):11923–11928. doi:https://doi.org/10.1073/pnas.1811520115.
- Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic. 2007;8(7):848–866. doi:https://doi.org/10.1111/j.1600-0854.2007.00572.x.
- Bernardes N, Fialho AM. Perturbing the dynamics and organization of cell membrane components: a new paradigm for cancer-targeted therapies. Int J Mol Sci. 2018;19(12):3871. doi:https://doi.org/10.3390/ijms19123871.
- Bernardes N, Garizo AR, Pinto SN, Caniço B, Perdigão C, Fernandes F, Fialho AM. Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs. Cell Cycle. 2018;17(13):1649–1666. doi:https://doi.org/10.1080/15384101.2018.1489178.
- Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61(11):953–964. doi:https://doi.org/10.1016/j.addr.2009.06.001.
- Zaro JL, Vekich JE, Tran T, Shen WC. Nuclear localization of cell-penetrating peptides is dependent on endocytosis rather than cytosolic delivery in CHO cells. Mol Pharm. 2009;6(2):337–344. doi:https://doi.org/10.1021/mp800239p.
- Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating peptides. Chem Biol. 2008;15(4):375–382. doi:https://doi.org/10.1016/j.chembiol.2008.03.015.
- Yamada Y, Satrialdi RM, Sakurai Y, Sakurai Y, Sakurai Y, Harashima H, Harashima H. Mitochondrial delivery of an anticancer drug via systemic administration using a mitochondrial delivery system that inhibits the growth of drug-resistant cancer engrafted on mice. J Pharm Sci. 2020;109(8):2493–2500. doi:https://doi.org/10.1016/j.xphs.2020.04.020.
- Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H. MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim et Biophys Acta. 2008;1778(2):423–432. doi:https://doi.org/10.1016/j.bbamem.2007.11.002.
- Zalba S, Ten Hagen TL. Cell membrane modulation as adjuvant in cancer therapy. Cancer Treat Rev. 2017;52:48–57. https://doi.org/https://doi.org/10.1016/j.ctrv.2016.10.008.
- Tan LT, Chan KG, Pusparajah P, Lee WL, Chuah LH, Khan TM, Lee LH, Goh BH. Targeting membrane lipid a potential cancer cure? Front. Pharmacol. 2017;8:12. doi:https://doi.org/10.3389/fphar.2017.00012.
- Kondo E, Saito K, Tashiro Y, Kamide K, Uno S, Furuya T, Mashita M, Nakajima K, Tsumuraya T, Kobayashi N, et al. Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nature Communications. 2012;3(1):951. doi:https://doi.org/10.1038/ncomms1952.
- Borrelli A, Tornesello AL, Tornesello ML, Buonaguro FM. Cell penetrating peptides as molecular carriers for anti-cancer agents. Molecules. 2018;23(2):295. doi:https://doi.org/10.3390/molecules23020295.
- Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284–293. doi:https://doi.org/10.1016/j.ab.2004.12.026.
- Meng F, Sun Y, Lee RJ, Wang G, Zheng X, Zhang H, Fu Y, Yan G, Wang Y, Deng W, et al. Folate receptor-targeted albumin nanoparticles based on microfluidic technology to deliver cabazitaxel. Cancers (Basel). 2019;11(10):1571. doi:https://doi.org/10.3390/cancers11101571.
- Xie J, Teng L, Yang Z, Zhou C, Liu Y, Yung BC, Lee RJ. A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide delivery. Biomed Res Int. 2013;2013:710502. https://doi.org/https://doi.org/10.1155/2013/710502.
- Xie J, Yang Z, Zhou C, Zhu J, Lee RJ, Teng L. Nanotechnology for the delivery of phytochemicals in cancer therapy. Biotechnol Adv. 2016;34(4):343–353. doi:https://doi.org/10.1016/j.biotechadv.2016.04.002.
- Yang Z, Yu B, Zhu J, Huang X, Xie J, Xu S, Yang X, Wang X, Yung BC, Lee LJ, et al. A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale. 2014;6(16):9742–9751. doi:https://doi.org/10.1039/C4NR01510J.
- Yang X, Yang S, Chai H, Yang Z, Lee RJ, Liao W, Teng L, Novel Isoquinoline A, Seno M. Derivative anticancer agent and its targeted delivery to tumor cells using transferrin-conjugated liposomes. PLoS One. 2015;10(8):e0136649. doi:https://doi.org/10.1371/journal.pone.0136649.
- Zhou C, Yang Z, Teng L. Nanomedicine based on nucleic acids: pharmacokinetic and pharmacodynamic perspectives. Curr Pharm Biotechnol. 2014;15(9):829–838. doi:https://doi.org/10.2174/1389201015666141020155620.
- Raucher D, Ryu JS. Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med. 2015;21(9):560–570. doi:https://doi.org/10.1016/j.molmed.2015.06.005.
- Habault J, Poyet JL. Recent advances in cell penetrating peptide-based anticancer therapies. Molecules. 2019;24(5):927. doi:https://doi.org/10.3390/molecules24050927.
- Shi NQ, Qi XR, Xiang B, Zhang Y. A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy”. J Control Release. 2014;194:53–70. doi:https://doi.org/10.1016/j.jconrel.2014.08.014.
- Tang H, Su ZD, Wei HH, Chen W, Lin H. Prediction of cell-penetrating peptides with feature selection techniques. Biochem. Biophys Res Commun. 2016;477(1):150–154. doi:https://doi.org/10.1016/j.bbrc.2016.06.035.
- Savariar EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P, Tsien RY, Nguyen QT. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res. 2013;73(2):855–864. doi:https://doi.org/10.1158/0008-5472.CAN-12-2969.
- Gronewold A, Horn M, Ranđelović I, Tóvári J, Vázquez SM, Schomäcker K, Neundorf I. Characterization of a cell-penetrating peptide with potential anticancer activity. Chem Med Chem. 2017;12(1):42–49. doi:https://doi.org/10.1002/cmdc.201600498.
- Hoyer J, Schatzschneider U, Schulz-Siegmund M, Neundorf I. Dimerization of a cell-penetrating peptide leads to enhanced cellular uptake and drug delivery. Beilstein J Org Chem. 2012;8:1788–1797. doi:https://doi.org/10.3762/bjoc.8.204.
- Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, Lekmine F, Tiruppathi C, Shilkaitis A, Bratescu L, et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2. FAK and Akt Angiogenesis. 2011;14(3):355–369. doi:https://doi.org/10.1007/s10456-011-9220-6.
- Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 2011;68:513–524. https://doi.org/https://doi.org/10.1007/s00280-010-1518-3.
- Yamada T, Gupta TKD, Beattie CW. p28-Mediated activation of p53 in G2–M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy. Cancer Res. 2016;76(8):2354–2365. doi:https://doi.org/10.1158/0008-5472.CAN-15-2355.
- Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, Cho JH, Kim SC. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 2008;271(1):47–55. doi:https://doi.org/10.1016/j.canlet.2008.05.041.
- Lim KJ, Sung BH, Shin JR, Lee YW, Kim DJ, Yang KS, Kim SC, Sobol RW. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One. 2013;8(6):e66084. doi:https://doi.org/10.1371/journal.pone.0066084.
- Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res. 1997;88(2):184–190. doi:https://doi.org/10.1111/j.1349-7006.1997.tb00364.x.
- Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther. 2005;4(4):612–624. doi:https://doi.org/10.1158/1535-7163.MCT-04-0077.
- Solarte VA, Conget P, Vernot JP, Rosas JE, Rivera ZJ, García JE, Arango-Rodríguez ML, Ahmad A. A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: a preclinical model. PLoS One. 2017;12(3):e0174707. doi:https://doi.org/10.1371/journal.pone.0174707.
- Guerra JR, Cárdenas AB, Ochoa-Zarzosa A, Meza JL, Umaña Pérez YA, Fierro-Medina R, Rivera Monroy ZJ, García Castañeda JE. The tetrameric peptide LfcinB (20–25) 4 derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line. RSC Adv. 2019;9(36):20497–20504. doi:https://doi.org/10.1039/C9RA04145A.
- Vargas Casanova Y, Rodríguez Guerra JA, Umaña Pérez YA, Leal Castro AL, Almanzar Reina G, García Castañeda JE, Rivera Monroy ZJ. Antibacterial synthetic peptides derived from bovine lactoferricin exhibit cytotoxic effect against MDA-MB-468 and MDA-MB-231 breast cancer cell lines. Molecules. 2017;22(10):1641. doi:https://doi.org/10.3390/molecules22101641.
- Liao HW, Garris C, Pfirschke C, Rickelt S, Arlauckas S, Siwicki M, Kohler RH, Weissleder R, Sundvold-Gjerstad V, Sveinbjørnsson B, et al. LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. Cell Stress. 2019;3(11):348–360. doi:https://doi.org/10.15698/cst2019.11.204.
- Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y, Liu P, Yang H, Bezu L, Müller K, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 2016;7(3):e2134. doi:https://doi.org/10.1038/cddis.2016.47.
- Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjørnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer immunol. Immunother. 2014;63(6):601–613. doi:https://doi.org/10.1007/s00262-014-1540-0.
- Nestvold J, Wang MY, Camilio KA, Zinöcker S, Tjelle TE, Lindberg A, Haug BE, Kvalheim G, Sveinbjørnsson B, Rekdal Ø. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology. 2017;6(8):e1338236. doi:https://doi.org/10.1080/2162402X.2017.1338236.
- Forveille S, Zhou H, Sauvat A, Bezu L, Müller K, Liu P, Zitvogel L, Pierron G, Rekdal Ø, Kepp O, et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle. 2015;14(21):3506–3512. doi:https://doi.org/10.1080/15384101.2015.1093710.
- Moghal MMR, Islam MZ, Sharmin S, Levadnyy V, Moniruzzaman M, Yamazaki M. Continuous detection of entry of cell-penetrating peptide transportan 10 into single vesicles. Chem Phys Lipids. 2018;212:120–129. https://doi.org/https://doi.org/10.1016/j.chemphyslip.2018.02.001.
- Moghal MMR, Islam MZ, Hossain F, Saha SK, Yamazaki M. Role of membrane potential on entry of cell-penetrating peptide transportan 10 into single vesicles. Biophys J. 2020;118(1):57–69. doi:https://doi.org/10.1016/j.bpj.2019.11.012.
- Moghal MMR, Hossain F, Yamazak M. Action of antimicrobial peptides and cell-penetrating peptides on membrane potential revealed by the single GUV method. Biophys Rev. 2020;12(2):339–348. doi:https://doi.org/10.1007/s12551-020-00662-z.
- Yandek LE, Pokorny A, Florén A, Knoelke K, Langel Ü, Almeida PFF. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J. 2007;92(7):2434–2444. doi:https://doi.org/10.1529/biophysj.106.100198.
- Cahill K. Molecular electroporation and the transduction of oligoarginines. Phys Biol. 2009;7(1):16001. doi:https://doi.org/10.1088/1478-3975/7/1/016001.
- Yamada T, Gupta TKD, Beattie CW. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol Pharm. 2013;10(9):3375–3383. doi:https://doi.org/10.1021/mp400221r.
- Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, Das Gupta TK, A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer. 2013, 108, 1061–1070. https://doi.org/https://doi.org/10.1038/bjc.2013.74
- Lulla RR, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, et al. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2016;18(9):1319–1325. doi:https://doi.org/10.1093/neuonc/now047.
- Bolhassani A, Jafarzade BS, Mardani G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2017;87:50–63. doi:https://doi.org/10.1016/j.peptides.2016.11.011.
- Shafiee F, Rabbani M, Jahanian-Najafabadi A. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. J Microbiol Methods. 2016;130:100–105. https://doi.org/https://doi.org/10.1016/j.mimet.2016.09.004.
- Zhang X, Lin C, Lu A, Lin G, Chen H, Liu Q, Yang Z, Zhang H, Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma. Drug Deliv. 2017; 24: 986–998. https://doi.org/https://doi.org/10.1080/10717544.2017.1340361
- Kebebe D, Liu Y, Wu Y, Vilakhamxay M, Liu Z, Li J. Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers. Int J Nanomedicine. 2018;13:1425–1442. doi:https://doi.org/10.2147/IJN.S156616.
- Jiang R, Lönnerdal B. Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017;95(1):99–109. doi:https://doi.org/10.1139/bcb-2016-0094.
- Zweytick D. LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent. Cell Stress. 2019;3(11):328–329. doi:https://doi.org/10.15698/cst2019.11.202.
- Hao Y, Yang N, Teng D, Wang X, Mao R, Wang J. A review of the design and modification of lactoferricins and their derivatives. Biometals. 2018;31(3):331–341. doi:https://doi.org/10.1007/s10534-018-0086-6.
- Sadiq IZ, Babagana K, Danlami D, Abdullahi LI, Khan AR. Molecular therapeutic cancer peptides: a closer look at bovine lactoferricin. AJBGMB. 2018;1:1–9. doi:https://doi.org/10.9734/ajbgmb/2018/v1i2471.
- Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K, Mortensen B, Serin G, Mirjolet JF, Bichat F, et al. Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide. J Med Chem. 2016;59(7):2918–2927. doi:https://doi.org/10.1021/acs.jmedchem.5b02025.
- Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Res. 2019;21(1):9. doi:https://doi.org/10.1186/s13058-018-1092-x.
- Sveinbjørnsson B, Camilio KA, Haug BE, Rekdal Ø. LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Med Chem. 2017;9(12):1339–1344. doi:https://doi.org/10.4155/fmc-2017-0088.
- Nakase I, Noguchi K, Aoki A, Takatani-Nakase T, Fujii I, Futaki S. Arginine-rich cell-penetrating peptide-modified extracellular vesicles for active macropinocytosis induction and efficient intracellular delivery. Sci Rep. 2017;7(1):1991. doi:https://doi.org/10.1038/s41598-017-02014-6.
- Guo Z, Peng H, Kang J, Sun D. Cell-penetrating peptides: possible transduction mechanisms and therapeutic applications. Biomed Rep. 2016;4(5):528–534. doi:https://doi.org/10.3892/br.2016.639.
- Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, Takehashi M, Tanaka S, Ueda K, Simpson JC, et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther. 2004;10(6):1011–1022. doi:https://doi.org/10.1016/j.ymthe.2004.08.010.
- Takeuchi T, Futaki S. Current understanding of direct translocation of arginine-rich cell-penetrating peptides and its internalization mechanisms. Chem Pharm Bull (Tokyo). 2016;64(10):1431–1437.
- He L, Sayers EJ, Watson P, Jones AT. Contrasting roles for actin in the cellular uptake of cell penetrating peptide conjugates. Scie Rep. 2018:8. doi:https://doi.org/10.1038/s41598-018-25600-8.
- Lafarga V, Sirozh O, Díaz-López I, Galarreta A, Hisaoka M, Zarzuela E, Boskovic J, Jovanovic B, Fernandez-Leiro R, Muñoz J, et al. Widespread displacement of DNA- and RNA-binding factors underlies toxicity of arginine-rich cell-penetrating peptides. EMBO J. 2021;40(13):103311. doi:https://doi.org/10.15252/embj.2019103311.
- Nakase I, Konishi Y, Ueda M, Saji H, Futaki S. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J Control Release. 2012;159(2):181–188. doi:https://doi.org/10.1016/j.jconrel.2012.01.016.
- Kristensen M, Nielsen HM. Cell-penetrating peptides as tools to enhance non-injectable delivery of biopharmaceuticals. Tissue Barriers. 2016;4(2):1178369–1178384. doi:https://doi.org/10.1080/21688370.2016.1178369.
- Kristensen M, Birch D, Nielsen HM. Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int J Mol Sci. 2016;17(2):185–202. doi:https://doi.org/10.3390/ijms17020185.
- Xue G, Liu Z, Wang L, Zu L. The role of basic residues in the fragmentation process of the lysine rich cell-penetrating peptide TP10. J Mass Spectrom. 2015;50(1):220–227. doi:https://doi.org/10.1002/jms.3524.
- El-Andaloussi S, Järver P, Johansson HJ, Langel Ü. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J. 2007;407(2):285–292. doi:https://doi.org/10.1042/BJ20070507.
- Song J, Kai M, Zhang W, Zhang J, Liu L, Zhang B, Liu X, Wang R. Cellular uptake of transportan 10 and its analogs in live cells: selectivity and structure-activity relationship studies. Peptides. 2011;32(9):1934–1941. doi:https://doi.org/10.1016/j.peptides.2011.07.018.
- Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008;36(12):4158–4171. doi:https://doi.org/10.1093/nar/gkn342.
- Durzyńska J, Przysiecka Ł, Nawrot R, Barylski J, Nowicki G, Warowicka A, Musidlak O, Goździcka-Józefiak A. Viral and other cell-penetrating peptides as vectors of therapeutic agents in medicine. J Pharmacol Exp Ther. 2015;354(1):32–42. doi:https://doi.org/10.1124/jpet.115.223305.
- Lelle M, Frick SU, Steinbrink K, Peneva K. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization. J Pept Sci. 2014;20(5):323–333. doi:https://doi.org/10.1002/psc.2617.
- Shi NQ, Gao W, Xiang B, Qi XR. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine. 2012;7:1613–1621. https://doi.org/https://doi.org/10.2147/IJN.S30104.
- Movafegh B, Jalal R, Mohammadi Z, Aldaghi SA. Poly-L-arginine: enhancing cytotoxicity and cellular uptake of doxorubicin and necrotic cell death. Anticancer Agents Med Chem. 2018;18(10):1448–1456. doi:https://doi.org/10.2174/1871520618666180412114750.
- Nasrolahi Shirazi A, Tiwari R, Chhikara BS, Mandal D, Parang K. A. Nasrolahi Shirazi, R. Tiwari, B.S. Chhikara, D. Mandal, K. Parang, Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharm. 2013;10(2):488–499. doi:https://doi.org/10.1021/mp3004034.
- Zhang P, Cheetham AG, Lock LL, Cui H. Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem. 2013;24(4):604–613. doi:https://doi.org/10.1021/bc300585h.
- Lee JY, Choi YS, Suh JS, Kwon YM, Yang VC, Lee SJ, Chung CP, Park YJ. Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer. 2011;128(10):2470–2480. doi:https://doi.org/10.1002/ijc.25578.
- Aroui S, Brahim S, de Waard M, Bréard J, Kenani A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009;285(1):28–38. doi:https://doi.org/10.1016/j.canlet.2009.04.044.
- Aroui S, Brahim S, Hamelin J, de Waard M, Bréard J, Kenani A, Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Apoptosis 2009; 14: 1352–1365. https://doi.org/https://doi.org/10.1007/s10495-009-0397-8
- Aroui S, Brahim S, Waard MD, Kenani A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Commun. 2010;391(1):419–425. doi:https://doi.org/10.1016/j.bbrc.2009.11.073.
- Chen Z, Zhang P, Cheetham AG, Moon JH, Moxley JW, Lin YA, Cui H. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release. 2014;191:123–130. https://doi.org/https://doi.org/10.1016/j.jconrel.2014.05.051.
- Liang JF, Yang VC. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett. 2005;15(22):5071–5075. doi:https://doi.org/10.1016/j.bmcl.2005.07.087.
- Lakkadwala S, Dos Santos Rodrigues B, Sun C, Singh J. Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo. Nanomedicine. 2020;23:102112. doi:https://doi.org/10.1016/j.nano.2019.102112.
- Liu Z, Xiong M, Gong J, Zhang Y, Bai N, Luo Y, Li L, Wei Y, Liu Y, Tan X, et al. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat Commun. 2014;5(1):4280. doi:https://doi.org/10.1038/ncomms5280.
- Sethuraman VA, Lee MC, Bae YH. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res. 2008;25(3):657–666. doi:https://doi.org/10.1007/s11095-007-9480-4.
- Lee ES, Gao Z, Kim D, Park K, Kwon IC, Bae YH. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release. 2008;129(3):228–236. doi:https://doi.org/10.1016/j.jconrel.2008.04.024.
- Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000;57(4):679–686. doi:https://doi.org/10.1124/mol.57.4.679.
- Aroui S, Mili D, Brahim S, de Waard M, Kenani A. Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase. Biochem Biophys Res Commun. 2010;396(4):908–914. doi:https://doi.org/10.1016/j.bbrc.2010.05.020.
- Aroui S, Dardevet L, Ben Ajmia W, De Boisvilliers M, Perrin F, Laajimi A, Boumendjel A, Kenani A, Muller JM, de Waard M, et al. Conjugate induces apoptosis of human glioblastoma cells by acting through the ROS-ERK/AKT-p53 pathway. Mol Pharm. 2015;12(12):4336–4348. doi:https://doi.org/10.1021/acs.molpharmaceut.5b00531.
- Ché C, Yang G, Thiot C, Lacoste JC, Demeule CM, Régina A, Béliveau R, Castaigne JP, Castaigne J-P. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem. 2010;53(7):2814–2824. doi:https://doi.org/10.1021/jm9016637.
- Figueiredo P, Balasubramanian V, Shahbazi M-A, Correia A, Wu D, Palivan CG, Hirvonen JT, Santos HA. Angiopep2-functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells. . International Journal of Pharmaceutics. 2016;511(2):794–803. doi:https://doi.org/10.1016/j.ijpharm.2016.07.066.
- Soudy R, Chen C, Kaur K. Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells. J Med Chem. 2013;56(19):7564–7573. doi:https://doi.org/10.1021/jm400647r.
- Yu M, Li X, Huang X, Zhang J, Zhang Y, Wang H. New cell-penetrating peptide (KRP) with multiple physicochemical properties endows doxorubicin with tumor targeting and improves its therapeutic index. ACS Appl Mater Interfaces. 2019;11(2):2448–2458. doi:https://doi.org/10.1021/acsami.8b21027.
- Li Y, Zheng X, Cao Z, Xu W, Zhang J, Gong M. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin. Int J Pharm. 2012;434(1–2):209–214. doi:https://doi.org/10.1016/j.ijpharm.2012.06.003.
- Rousselle C, Smirnova M, Clair P, Lefauconnier JM, Chavanieu A, Calas B, Scherrmann JM, Temsamani J. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther. 2001;296:124–131.
- Liu Y, Ran R, Chen J, Kuang Q, Tang J, Mei L, Zhang Q, Gao H, Zhang Z, He Q. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials. 2014;35(17):4835–4847. doi:https://doi.org/10.1016/j.biomaterials.2014.02.031.
- Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci USA. 2008;105(34):12128–12133. doi:https://doi.org/10.1073/pnas.0805374105.
- Pepe D, Carvalho VF, McCall M, de Lemos DP, Lopes LB. Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel. Int J Nanomedicine. 2016;11:2009–2019. https://doi.org/https://doi.org/10.2147/IJN.S97331.
- Duan Z, Chen C, Qin J, Liu Q, Wang Q, Xu X, Wang J. Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer. Drug Deliv. 2017;24(1):752–764. doi:https://doi.org/10.1080/10717544.2017.1321060.
- Wang S, Zhelev NZ, Duff S, Fischer PM. Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. Bioorg Med Chem Lett. 2006;16(10):2628–2631. doi:https://doi.org/10.1016/j.bmcl.2006.02.035.
- Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012;11(2):308–316. doi:https://doi.org/10.1158/1535-7163.MCT-11-0566.
- Régina A, Demeule M, Ché C, Lavallée I, Poirier J, Gabathuler R, Béliveau R, Castaigne JP. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155(2):185–197. doi:https://doi.org/10.1038/bjp.2008.260.
- Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Mikkelsen GT, Meyers CA, Meyers CA, Meyers CA, Fielding RM, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19(6):1567–1576. doi:https://doi.org/10.1158/1078-0432.CCR-12-2481.
- Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials. 2010;31(8):2278–2292. doi:https://doi.org/10.1016/j.biomaterials.2009.11.047.
- Ho K, Morfin C, Slowinska K. The limitations of collagen/CPP hybrid peptides as carriers for cancer drugs to FaDu cells. Molecules. 2019;24(4):676. doi:https://doi.org/10.3390/molecules24040676.
- Ayalew L, Acuna J, Urfano SF, Morfin C, Sablan A, Oh M, Gamboa A, Slowinska K. Conjugation of paclitaxel to hybrid peptide carrier and biological evaluation in Jurkat and A549 cancer cell lines. ACS Med Chem Lett. 2017;8(8):814–819. doi:https://doi.org/10.1021/acsmedchemlett.7b00117.
- Gao W, Xiang B, Meng TT, Liu F, Qi XR. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials. 2013;34(16):4137–4149. doi:https://doi.org/10.1016/j.biomaterials.2013.02.014.
- Mäe M, Rautsi O, Enbäck J, Hällbrink M, Aizman KR, Lindgren M, Laakkonen P, Langel Ü. Tumour targeting with rationally modified cell-penetrating peptides. Int J Pept Res and Ther. 2012;18(4):361–371. doi:https://doi.org/10.1007/s10989-012-9312-1.
- Lindgren M, Rosenthal-Aizman K, Saar K, Eiríksdóttir E, Jiang Y, Sassian M, Ostlund P, Hällbrink M, Langel Ü. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 2006;71(4):416–425. doi:https://doi.org/10.1016/j.bcp.2005.10.048.
- Szabó I, Orbán E, Schlosser G, Hudecz F, Bánóczi Z. Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells. Eur J Med Chem. 2016;115:361–368. https://doi.org/https://doi.org/10.1016/j.ejmech.2016.03.034.
- Vale N, Ferreira A, Fernandes I, Alves C, Araújo MJ, Mateus N, Gomes P. Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides. Bioorg Med Chem Lett. 2017;27(13):2898–2901. doi:https://doi.org/10.1016/j.bmcl.2017.04.086.
- Ferreira A, Lapa R, Vale N. Combination of Gemcitabine with cell-penetrating peptides: a pharmacokinetic approach using in silico tools. Biomolecules. 2019;9(11):693. doi:https://doi.org/10.3390/biom9110693.
- Kwon YM, Chung HS, Moon C, Yockman J, Park YJ, Gitlin SD, David AEVC, Yang VC. Yang, L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release. 2009;139(3):182–189. doi:https://doi.org/10.1016/j.jconrel.2009.06.027.
- Kwon YM, Li YT, Liang JF, Park YJ, Chang LC, Yang VC. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release. 2008;130(3):252–258. doi:https://doi.org/10.1016/j.jconrel.2008.06.017.
- Myrberg H, Zhang L, Mäe M, Langel Ü. Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem. 2008;19(1):70–75. doi:https://doi.org/10.1021/bc0701139.
- Klimpel A, Neundorf I. Bifunctional peptide hybrids targeting the matrix of mitochondria. J Control Release. 2018;291:147–156. https://doi.org/https://doi.org/10.1016/j.jconrel.2018.10.029.
- Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int J Nanomedicine. 2016;11:6207–6216. doi:https://doi.org/10.2147/IJN.S110274.
- Song J, Zhang Y, Zhang W, Chen J, Yang X, Ma P, Zhang B, Liu B, Ni J, Wang R. Cell penetrating peptide TAT can kill cancer cells via membrane disruption after attachment of camptothecin. Peptides. 2015;63:143–149. doi:https://doi.org/10.1016/j.peptides.2014.12.001.
- Taki H, Kanazawa T, Akiyama F, Takashima Y, Okada H. Intranasal delivery of camptothecin-loaded tat-modified nanomicells for treatment of intracranial brain tumors. Pharmaceuticals (Basel). 2012 Oct 15;5(10):1092–1102. PMID: 24281259; PMCID: PMC3816654. doi:https://doi.org/10.3390/ph5101092.
- Feni L, Parente S, Robert C, Gazzola S, Arosio D, Piarulli U, Neundorf I. Kiss and run: promoting effective and targeted cellular uptake of a drug delivery vehicle composed of an integrin-targeting diketopiperazine peptidomimetic and a cell-penetrating peptide. Bioconjug Chem. 2019;30(7):2011–2202. doi:https://doi.org/10.1021/acs.bioconjchem.9b00292.
- Koshkaryev A, Piroyan A, Torchilin VP. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett. 2013;334(2):293–301. doi:https://doi.org/10.1016/j.canlet.2012.06.008.
- Spicer JF, Marabelle A, Baurain J, Awada A, Kristeleit RS, Jossang DE, Jebsen N, Loirat D, Armstrong AC, Curigliano G, et al. A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):3094. doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.3094.
- Eid RA, Razavi GS, Mkrtichyan M, Janik J, Khleif SN. Old-School chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res. 2016;4(5):377–382. doi:https://doi.org/10.1158/2326-6066.CIR-16-0048.
- Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74(1):104–118. doi:https://doi.org/10.1158/0008-5472.CAN-13-1545.
- Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011;10(1):69–79. doi:https://doi.org/10.1158/1535-7163.MCT-10-0581.
- Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, French DM. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004;64(20):7226–7230. doi:https://doi.org/10.1158/0008-5472.CAN-04-2601.
- Johnson N, Shapiro G. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets. 2010;14(11):1199–1212. doi:https://doi.org/10.1517/14728222.2010.525221.
- Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750–763. doi:https://doi.org/10.1038/nrc903.
- Terwogt JMM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001;12(4):315–323. doi:https://doi.org/10.1097/00001813-200104000-00003.
- De Coupade C, Fittipaldi A, Chagnas V, Michel M, Carlier S, Tasciotti E, Darmon A, Ravel D, Kearsey J, Giacca M, et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J. 2005;390(2):407–418. doi:https://doi.org/10.1042/BJ20050401.
- Senter PD, Beam KS, Mixan B, Wahl AF. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem. 2001;12(6):1074–1080. doi:https://doi.org/10.1021/bc0155420.
- Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–3725.
- Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V, De Coupade C, Boukaissi M, Chéné AS, Tranchant I, et al. DTS-108, A novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin Cancer Res. 2008;14(7):2145–2153. doi:https://doi.org/10.1158/1078-0432.CCR-07-4580.
- Demeule M, Régina A, Ché C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Béliveau R. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324(3):1064–1072. doi:https://doi.org/10.1124/jpet.107.131318.
- Cai W, Chen G, Luo Q, Liu J, Guo X, Zhang T, Ma F, Yuan L, Li B, Cai J. PMP22 regulates self-renewal and chemoresistance of gastric cancer cells. Molecular Cancer Therapeutics. 2017;16(6):1187–1198. doi:https://doi.org/10.1158/1535-7163.MCT-16-0750.
- Aroui S, Ram N, Appaix F, Ronjat M, Kenani A, Pirollet F, de Waard M. Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. Pharm Res. 2009;26(4):836–845. doi:https://doi.org/10.1007/s11095-008-9782-1.
- Aroui S, Kenani A. Cell-penetrating peptides: a challenge for drug delivery. In: Stefaniu A, Rasul A, Hussain G, editors. Cheminformatics and its Applications. Rijeka, Croatia, IntechOpen Limited; 2020. p. 209. doi:https://doi.org/10.5772/intechopen.91684.
- Ronjat M, Feng W, Dardevet L, Dong Y, Khoury SA, Chatelain FC, Vialla V, Chahboun S, Lesage F, Darbon H, et al. In cellulo phosphorylation induces pharmacological reprogramming of maurocalcin, a cell-penetrating venom peptide. PNAS. 2016;113(17):E2460–E2468. doi:https://doi.org/10.1073/pnas.1517342113.
- Boisseau S, Mabrouk K, Ram N, Garmy N, Collin V, Tadmouri A, Mikati M, Sabatier JM, Ronjat M, Fantini J, et al. Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochim Biophys Acta. 2006;1758(3):308–319. doi:https://doi.org/10.1016/j.bbamem.2006.02.007.
- Alves ID, Bechara C, Walrant A, Zaltsman Y, Jiao CY, Sagan S, Gasset M. Relationships between membrane binding, affinity and cell internalization efficacy of a cell-penetrating peptide: penetratin as a case study. PLoS One. 2011;6(9):e24096. doi:https://doi.org/10.1371/journal.pone.0024096.
- Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem. 2009;284(49):33957–33965. doi:https://doi.org/10.1074/jbc.M109.056309.
- Zhang X, Zhang X, Wang X, Wang T, Bai B, Zhang N, Zhao Y, Yu Y, Wang B. Efficient delivery of triptolide plus a mir-30-5p inhibitor through the use of near infrared laser responsive or CADY modified MSNs for efficacy in rheumatoid arthritis therapeutics. Front Bioeng Biotechnol. 2020;8:170. https://doi.org/https://doi.org/10.3389/fbioe.2020.00170.
- Park YJ, Liang JF, Ko KS, Kim SW, Yang VC. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med. 2003;5(8):700–711. doi:https://doi.org/10.1002/jgm.402.
- Elmquist A, Lindgren M, Bartfai T, Langel U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res. 2001;269(2):237–244. doi:https://doi.org/10.1006/excr.2001.5316.
- Elmquist A, Hansen M, Langel Ü. Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochim Biophys Acta. 2006;1758(6):721–729. doi:https://doi.org/10.1016/j.bbamem.2006.05.013.